News

RIBOCICLIB PLUS BINIMETINIB FOR PATIENTS WITH WITH NRAS-MUTATED MELANOMA

News /

Patients with melanoma have some relevant mutations, the most frequent being the BRAF mutation (40-60% of patients); this biomarker is also fundamental due to the success of the therapeutic target associated with it. Other relevant mutations are found in the NRAS genes (15-25% of cases), KIT, TERT and in the case of uveal melanomas, GNAQ […]

RIBOCICLIB PLUS BINIMETINIB FOR PATIENTS WITH WITH NRAS-MUTATED MELANOMA Read More »

PEMIGATINIB FOR PAN-CANCER PATIENTS WITH FGF/FGFR-POSITIVE ADVANCED MALIGNANCIES

News /

This phase I/II trial evaluated the safety, activity, and efficacy of pemigatinib, a selective FGFR 1–3 inhibitor, in patients with refractory advanced malignancies, with or without FGF and FGFR gene alterations. Pemigatinib demonstrated a favorable safety profile and pharmacologic/clinical activity in a variety of solid tumor types, including cholangiocarcinoma, urothelial carcinoma, recurrent pilocytic astrocytoma and

PEMIGATINIB FOR PAN-CANCER PATIENTS WITH FGF/FGFR-POSITIVE ADVANCED MALIGNANCIES Read More »

A NOVEL THIRD-GENERATION EGFR TYROSINE KINASE INHIBITOR ABIVERTINIB FOR EGFR T790M-MUTANT NON–SMALL CELL LUNG CANCER: A MULTICENTER PHASE I/II STUDY

News /

In this phase I/II trial, the authors investigated a novel third-generation EGFR tyrosine kinase inhibitor (TKI), abivertinib, in patients with non-small cell lung cancer and harboring the T790M resistance mutation. Abivertinib demonstrated favorable efficacy and a tolerable safety profile in patients. Specifically among the 209 patients evaluated, the objective response rate (ORR) was 52.2% (95%

A NOVEL THIRD-GENERATION EGFR TYROSINE KINASE INHIBITOR ABIVERTINIB FOR EGFR T790M-MUTANT NON–SMALL CELL LUNG CANCER: A MULTICENTER PHASE I/II STUDY Read More »

EGFR AND HER2 EXON 20 INSERTIONS IN SOLID TUMOURS: FROM BIOLOGY TO TREATMENT

News /

Protein tyrosine kinases of the human epidermal growth factor receptor family, including EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung, breast and gastroesophageal cancers, and are of relevance for the treatment of various other malignancies (particularly colorectal cancer). Classic activating EGFR exon 19 deletions and exon 21 mutations, and HER2 amplification and/or overexpression, are predictive

EGFR AND HER2 EXON 20 INSERTIONS IN SOLID TUMOURS: FROM BIOLOGY TO TREATMENT Read More »

NEW TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER APPROVED

News /

The EMA has approved a new drug for the benefit of patients with non-small cell lung cancer (NSCLC). It is amivantamab (Janssen), a new drug for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion activating mutations, following the failure of platinum-based therapy.

NEW TREATMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER APPROVED Read More »

MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION

News /

The authors report the 5-year follow-up data for the SOLO1 trial. Progression-free survival (PFS) was significantly longer with olaparib compared with placebo, and durable PFS benefits were seen with 2 years of maintenance olaparib therapy in patients with BRCA-mutated, newly diagnosed, advanced, high-grade serous or endometrioid ovarian cancer with a complete or partial response after

MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER AND A BRCA MUTATION Read More »

MOLECULAR DETERMINANTS OF OUTCOMES WITH PEMBROLIZUMAB VS PACLITAXEL IN PATIENTS WITH GASTROESOPHAGEAL ADENOCARCINOMA

News /

In this exploratory analysis of KEYNOTE-061, the authors demonstrated a strong association between tissue tumor mutational burden (tTMB) and efficacy of second-line pembrolizumab in patients with gastric and gastroesophageal cancer, suggesting that tTMB is an independent predictor beyond PD-L1 status. There was a low correlation between whole-exome sequencing (WES)-tTMB and the PD-L1 combined positive score.

MOLECULAR DETERMINANTS OF OUTCOMES WITH PEMBROLIZUMAB VS PACLITAXEL IN PATIENTS WITH GASTROESOPHAGEAL ADENOCARCINOMA Read More »

ENCORAFENIB PLUS CETUXIMAB AS A NEW STANDARD OF CARE FOR PREVIOUSLY TREATED BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: UPDATED SURVIVAL RESULTS AND SUBGROUP ANALYSES FROM THE BEACON STUDY

News /

BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators’ choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), after progression on 1-2 prior regimens. In the previously reported primary analysis, encorafenib, binimetinib plus cetuximab (ENCO/BINI/CETUX; triplet) and encorafenib plus cetuximab (ENCO/CETUX; doublet) regimens improved overall survival

ENCORAFENIB PLUS CETUXIMAB AS A NEW STANDARD OF CARE FOR PREVIOUSLY TREATED BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: UPDATED SURVIVAL RESULTS AND SUBGROUP ANALYSES FROM THE BEACON STUDY Read More »

FDA APPROVES PEMBROLIZUMAB FOR ADVANCED OR METASTATIC ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER

News /

The United States Food and Drug Administration (FDA) has granted approval for Merck’s anti-programmed death ligand-1 (PD-L1) therapy pembrolizumab (Keytruda) to be used in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) carcinoma. The approval applies specially to treatment of tumors with an epicenter 1

FDA APPROVES PEMBROLIZUMAB FOR ADVANCED OR METASTATIC ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER Read More »

Descargar más información